LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Roche Holding AG (“Roche” or the “Company”) (Other OTC: RHHBY).
If you purchased or otherwise acquired Roche shares, and would like more information about the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you.
The investigation focuses on whether Roche and certain of its officers and/or directors violated federal securities laws. On June 5, 2017, news reports stated that a new study showed that adding Roche’s breast cancer drug Perjeta to its older treatment Herceptin only had a slight benefit while more than doubling the one-year treatment cost; and that the combination of Perjeta with Herceptin had higher rates of certain side effects than Herceptin alone, including severe diarrhea. When this news was announced, the Company’s shares decreased in value.
If you have any questions about your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.